{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T13:55:47Z","timestamp":1760622947077,"version":"3.40.5"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,6,1]],"date-time":"2015-06-01T00:00:00Z","timestamp":1433116800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,2,27]],"date-time":"2015-02-27T00:00:00Z","timestamp":1424995200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pulmonary Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2015,6]]},"DOI":"10.1016\/j.pupt.2015.02.008","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T23:31:34Z","timestamp":1425339094000},"page":"101-108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D"],"prefix":"10.1016","volume":"32","author":[{"given":"Huib A.M.","family":"Kerstjens","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4919-5916","authenticated-orcid":false,"given":"Ga\u00ebtan","family":"Desl\u00e9e","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Dahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James F.","family":"Donohue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Kornmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pupt.2015.02.008_bib1","unstructured":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (Updated 2013). http:\/\/www.goldcopd.org\/."},{"issue":"1","key":"10.1016\/j.pupt.2015.02.008_bib2","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/S2213-2600(13)70015-8","article-title":"GOLD COPD categories are not fit for purpose in primary care","volume":"1","author":"Jones","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"10","key":"10.1016\/j.pupt.2015.02.008_bib3","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1164\/rccm.201210-1873ED","article-title":"Global initiative on obstructive lung disease revised. What constitutes a guideline?","volume":"187","author":"Rabe","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.pupt.2015.02.008_bib4","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S2213-2600(12)70045-0","article-title":"GOLD and ABCD-a good start, but now for the evidence?","volume":"1","author":"Wedzicha","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"6","key":"10.1016\/j.pupt.2015.02.008_bib5","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1136\/thx.2009.125435","article-title":"Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD","volume":"65","author":"Dahl","year":"2010","journal-title":"Thorax"},{"issue":"2","key":"10.1016\/j.pupt.2015.02.008_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.200910-1500OC","article-title":"Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium","volume":"182","author":"Donohue","year":"2010","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.pupt.2015.02.008_bib7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1183\/09031936.00045810","article-title":"Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison","volume":"37","author":"Kornmann","year":"2011","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.pupt.2015.02.008_bib8","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1183\/09031936.00099306","article-title":"Outcomes for COPD pharmacological trials: from lung function to biomarkers","volume":"31","author":"Cazzola","year":"2008","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.pupt.2015.02.008_bib9","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/COPD-200050513","article-title":"St. George's respiratory Questionnaire: MCID","volume":"2","author":"Jones","year":"2005","journal-title":"COPD"},{"issue":"1","key":"10.1016\/j.pupt.2015.02.008_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1081\/COPD-200050666","article-title":"The MCID of the transition dyspnea index is a total score of one unit","volume":"2","author":"Mahler","year":"2005","journal-title":"COPD"},{"issue":"13","key":"10.1016\/j.pupt.2015.02.008_bib11","first-page":"10","article-title":"Characteristics of a COPD population categorised using the GOLD framework by health status and exacerbations","author":"Jones","year":"2013","journal-title":"Respir Med"},{"issue":"9","key":"10.1016\/j.pupt.2015.02.008_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1164\/rccm.201105-0831OC","article-title":"The progression of chronic obstructive pulmonary disease is heterogeneous: the experience of the BODE cohort","volume":"184","author":"Casanova","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.pupt.2015.02.008_bib13","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1183\/09031936.00125612","article-title":"Comparisons of health status scores with MRC grades in COPD: implications for the GOLD 2011 classification","volume":"42","author":"Jones","year":"2013","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.pupt.2015.02.008_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/1465-9921-14-100","article-title":"Comparative efficacy of long-acting bronchodilators for C","volume":"14","author":"Cope","year":"2013","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.pupt.2015.02.008_bib15","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1183\/09031936.00191810","article-title":"Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD","volume":"38","author":"Buhl","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.pupt.2015.02.008_bib16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/1465-9921-13-52","article-title":"Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium","volume":"13","author":"Beeh","year":"2012","journal-title":"Respir Res"}],"container-title":["Pulmonary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000279?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1094553915000279?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,24]],"date-time":"2018-09-24T14:28:59Z","timestamp":1537799339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1094553915000279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6]]},"references-count":16,"alternative-id":["S1094553915000279"],"URL":"https:\/\/doi.org\/10.1016\/j.pupt.2015.02.008","relation":{},"ISSN":["1094-5539"],"issn-type":[{"type":"print","value":"1094-5539"}],"subject":[],"published":{"date-parts":[[2015,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D","name":"articletitle","label":"Article Title"},{"value":"Pulmonary Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pupt.2015.02.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}